Background: The National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance on spinal cord stimulation (SCS) was published in 2008 and updated in 2012 with no change. This guidance recommends SCS as a cost effective treatment for patients with neuropathic pain. Objective: To assess the impact of NICE guidance by comparing SCS uptake in England pre-(2008-2009) and post-(2009-2012) NICE guidance. We also compared the English SCS uptake rate with Belgium, Netherlands, France and Germany. Design: SCS implant data for England was obtained from the Hospital Episode Statistics database (HES) and compared with other European countries where comparable data were available.
• We examined the impact of the NICE Technology Appraisal on the overall uptake of spinal cord stimulation in England, in addition to regional variations in patient access.
Key Messages
• The NICE Technology Appraisal publication appears to have had minimal impact on the uptake of spinal cord stimulation for new patients, and inequity of patient access remains despite clear evidence that this treatment is a cost-effective use of NHS resources.
• Reasons for this are multifactorial and include lack of guideline awareness, commissioning variation, lack of enforcement of NICE guidance and limited capacity at implanting centres.
• Some of these patient access barriers may be addressed with centralised commissioning of specialised services including spinal cord stimulation.
Strengths/limitations
• This study contributes a novel data analysis in the area of spinal cord stimulation, which highlights a lack of uptake of a cost-effective technology within the NHS. i.e. the variation in the availability and quality of NHS treatments and care in England and Wales (1, 2) . NICE publishes various types of guidance including Technology Appraisals (TA), Clinical Guidelines, Quality Standards and Interventional Procedures Guidance (2).
The TA guidance is based on evaluations of clinical and cost-effectiveness of selected technologies. The NHS is legally obliged to provide funding for medicines and treatments recommended within 3 months of the guidance (1) . In December 2011, The Department of Health announced in its Innovation, Health and Wealth report that commissioners are expected to provide access to new treatments within 90 days of approval (1, 3) . NICE TA guidance 159 on Spinal Cord Stimulation (SCS) for chronic pain of neuropathic or ischaemic origin was published in October 2008 and reviewed in January 2012 when no changes were made (4). This TA guidance approves SCS for adults with continued chronic neuropathic pain (measuring at least 50mm on 0-100mm visual analogue score) for at least 6 months despite all standard conventional treatment and after undergoing a successful trial of SCS by a multidisciplinary team (4).
We examined the data for SCS uptake in England between 2008 and 2012 in order to assess the impact of NICE TA guidance implementation. We compared this to the SCS implant rate in other European countries. Data was also requested from all Primary Care Trusts via a Freedom of Information request with regards to their SCS commissioning policy to determine whether a policy around the implementation of NICE guidance was in place or whether Individual Funding Requests (IFR) were being used. publication for SCS procedural activity was obtained from the Hospital Episode Statistics (HES) database (5) , using the QUANTIS system via NHiS (6). HES is a national statistical data warehouse for England of the care provided by NHS hospitals. QUANTIS is a database of NHS and social care numerical data for the UK and NHiS is a vendor that provides subscribed access to the QUANTIS database.
We examined OPCS-4 procedure codes A48.3 (Implantation of neurostimulator adjacent to spinal cord), A48.4 (Attention to neurostimulator adjacent to spinal cord) and A48.7 (Insertion of neurostimulator electrodes into spinal cord). The OPCS code A48.3 was assumed to reflect new permanent SCS implants, code A48.4 to contain both replacements and revisions, and code A48.7 to represent trial procedures. OPCS code 48.4 does not allow for a clear differentiation between battery replacement and revisions.
The relevant SCS codes were filtered by indication to ensure that only back pain and spinal indications were included. This eliminated any inclusion of other types of neurostimulation that may have been miscoded, for example for bowel and bladder indications. SCS uptake results are expressed per million populations across each Strategic Health Authority regions in England. We also compared uptake rates across Primary Care Trusts (PCT).
Oracle (11g Database) and Excel (Microsoft Office 2010 Pro) software programmes were utilised for the data analysis. We compared English SCS uptake data from 2011-12 (code A48.3 only) with European counties where we able to source the appropriate equivalent data, i.e. France, Belgium, Germany and the Netherlands (7) .
Results
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Despite mandatory TA guidance on SCS, the majority of PCTs required Individual Funding Requests (IFR) for each patient (Figure 4 ). Some PCTs rated SCS as a low priority procedure. The reasons for the barriers to funding are multifactorial and include lack of awareness of SCS referral guidelines, lack of NICE TAG enforcement at regional and national level, as well as a limitation of clinical capacity at implanting centres. Due to the limitations of the available data it is not possible to disentangle the factors responsible for the continuing inequity of funding for SCS implants. Yet we can comment that there has been no significant increase in the number of implanting centres. The capacity within existing centres is not showing a growth curve as expected in response to the NICE guidance. Only 10.8% of PCTs implemented NICE guidance as a funding policy ( Figure   4 ). It is possible that piecemeal funding and the difficulties associated with such an approach, as well as the impact of the marked regional variations, have prevented the expansion of current providers. The reported incidence of failed back surgery syndrome is estimated as 10-40% of patients undergoing back surgery (15) . In recent survey of the United Kingdom, 53% of pain clinics estimated 10% of their referrals comprised of failed back surgery syndrome patients and the remaining 47% of pain clinics estimated it as 20-30% of their referrals, therefore lack of candidates is unlikely (16) .
In a comparison to France, Germany, Belgium and the Netherlands, England has the lowest rate of implants per million of the population. Smaller countries show a much higher rate of SCS implants (7) , with Belgium and the Netherlands implanting 84.6 and 54.3 per million of population respectively. Nevertheless, for Belgium and the Netherlands only one
year of data is available therefore we are unable to comment on trends. Data for France was available for the last three years (Table 1b ) and shows no significant increase in SCS implants. The main indications for SCS are similar across the four countries i.e. failed back surgery syndrome or radicular pain, phantom pain, peripheral nerve injury, traumatic brachial plexus injury, spinal lesion, diabetic polyneuropathy and post herpetic neuralgia (7) . Focusing on the most common indication for SCS of failed back surgery syndrome, it is estimated that 10-40% of patients undergoing spinal surgery will develop neuropathic pain (15) . According to HES database, the number of spinal surgery procedures in England (17) . Assuming that one third of these procedures is being carried out for pain, the annual estimate will be 78,533 procedures of which 10% to 40 % (7,853 to 31,414) would be expected to be eligible for SCS treatment (16) . Based on this data, less than 2% of the eligible population of neuropathic patients in England are currently receiving SCS treatment.
Conclusion
Our study shows that NICE TA 159 has had minimal impact on the uptake of SCS for new patients, and rates of SCS implantation were highly variable across Strategic Health
Authorities and PCTs. The reasons for the lack of impact appear to be multifactorial.
Within the new arrangements of NHS England, where SCS is deemed to be a prescribed specialised service that will be commissioned centrally, some of these barriers may be and approving the final version of the manuscript.
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Conclusion:
Despite the positive NICE recommendation for the routine use of SCS, we found no evidence of a significant impact on SCS uptake in England. Rates of SCS implantation in England are lower than many other European countries. • We examined the impact of the NICE Technology Appraisal on the overall uptake of spinal cord stimulation in England, in addition to regional variations in patient access.
Key Messages
• The NICE Technology Appraisal publication appears to have had negligible impact on the uptake of spinal cord stimulation for new patients, and inequity of patient access remains despite clear evidence that this treatment is a cost-effective use of NHS resources.
Strengths/limitations
• This study contributes a novel data analysis in the area of spinal cord stimulation, which highlights a lack of uptake of a cost-effective technology within the NHS.
• Our findings are based on data extracted from the Hospital Episodes Statistics database which relies on hospital coded data on procedures and indications. We also compared uptake rates across Primary Care Trusts (PCT).
Results
The HES data analysis for year 2008-2012 showed a small increase in procedure codes 48.3 and 48.4 (Table 1a ) and large increase in procedure code 48.7. Figure 2 illustrates the activity trends for each separate procedure code. On analysis of each of the procedure codes, the increase in SCS procedures appears to be driven primarily by replacements, revisions and a large increase in trial activity. There was considerable variation in the rate of SCS uptake across Strategic Health Authorities throughout this time horizon. The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 47 48 One of the Right Care objectives for 2011-2012 is to minimise this unwarranted variation and maximise value (9) . Value can be increased by improving quality, optimising resource utilisation and ensuring that patients receive appropriate interventions.
Our findings are in contrast with a NICE implementation report (11) that shows a generally effective impact of guidance for surgical procedures. For example, laparoscopic colorectal surgeries occurred at higher rate than forecasted by NICE (TA 105) (12) . Laparoscopic inguinal hernia repair uptake increased following guidance, but it stabilised at lower levels than NICE forecasted (TA 83) (13). In addition, there was overall increase in bariatric surgery for morbid obesity following NICE guidance (CG 43) (14). Our study provides data on the marked variability in rate of SCS uptake at both health authority and PCT level.
NICE assessed SCS as a highly cost-effective treatment for failed back surgery syndrome with an incremental £10,480 per quality adjusted life year (QALY) ratio compared with with repeat back operation (4). These ratios are considerably below the UK willingness to pay threshold of £20,000 to 30,000 per QALY.
Despite mandatory TA guidance on SCS, the majority of PCTs required Individual Funding Requests (IFR) for each patient (Figure 4) . Some PCTs rated SCS as a low priority procedure. The reasons for the barriers to funding are multifactorial and include lack of awareness of SCS referral guidelines, lack of NICE TAG enforcement at regional and national level, as well as a limitation of clinical capacity at implanting centres. Due to the limitations of the available data it is not possible to disentangle the factors responsible for the continuing inequity of funding for SCS implants. Yet we can comment that there has been no significant increase in the number of implanting centres. The capacity within existing centres is not showing a growth curve as expected in response to the NICE guidance. Only 10.8% of PCTs implemented NICE guidance as a funding policy ( Figure   4 ). It is possible that piecemeal funding and the difficulties associated with such an approach, as well as the impact of the marked regional variations, have prevented the expansion of current providers. The reported incidence of failed back surgery syndrome is estimated as 10-40% of patients undergoing back surgery (15) . In recent survey of the United Kingdom, 53% of pain clinics estimated 10% of their referrals comprised of failed back surgery syndrome patients and the remaining 47% of pain clinics estimated it as 20-30% of their referrals, therefore lack of candidates is unlikely (16) .
In a comparison to France, Germany, Belgium and the Netherlands, England has the lowest rate of implants per million of the population. Smaller countries show a much higher rate of SCS implants (7), with Belgium and the Netherlands implanting 84.6 and 54.3 per million of population respectively. Nevertheless, for Belgium and the Netherlands only one
year of data is available therefore we are unable to comment on trends. Data for France was available for the last three years (Table 1b ) and shows no significant increase in SCS implants. The main indications for SCS are similar across the four countries i.e. failed back surgery syndrome or radicular pain, phantom pain, peripheral nerve injury, traumatic brachial plexus injury, spinal lesion, diabetic polyneuropathy and post herpetic neuralgia (7) . Focusing on the most common indication for SCS of failed back surgery syndrome, it is estimated that 10-40% of patients undergoing spinal surgery will develop neuropathic pain (15) . According to HES database, the number of spinal surgery procedures in England (17) . Assuming that one third of these procedures is being carried out for pain, the annual estimate will be 78,533 procedures of which 10% to 40 % (7,853 to 31,414) would be expected to be eligible for SCS treatment (16) . Based on this data, less than 2% of the eligible population of neuropathic patients in England are currently receiving SCS treatment. A lack of awareness of SCS as a clinical and costeffective treatment option amongst referring physicians may be hindering the uptake of this NICE-approved technology. More constructive engagement with the wider population of patients and referring physicians by the neuromodulation community is warranted to ensure appropriate and early referral for SCS therapy.
Conclusion
Our study shows that NICE TA 159 has had negligible impact on the uptake of SCS for new patients, and rates of SCS implantation were highly variable across Strategic Health
Authorities and PCTs. The reasons for the lack of impact appear to be multifactorial and may include limited awareness of SCS as an clinical and cost-effective treatment option amongst the wider referral community. Within the new arrangements of NHS England, where SCS is deemed to be a prescribed specialised service that will be commissioned centrally, some of these barriers may be addressed including a shift towards more equitable access to this technology, and elimination of the use of Individual Funding Requests.
Future implementation of NICE Innovation Scorecards to track compliance with NICE
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Key Messages
• The NICE Technology Appraisal publication appears to have had minimal negligible impact on the uptake of spinal cord stimulation for new patients, and inequity of patient access remains despite clear evidence that this treatment is a cost-effective use of NHS resources.
Strengths/limitations
• This study contributes a novel data analysis in the area of spinal cord stimulation, which highlights a lack of uptake of a cost-effective technology within the NHS. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We examined the data for SCS uptake in England between 2008 and 2012 in order to assess the impact of NICE TA guidance implementation. We compared this to the SCS implant rate in other European countries. Data was also requested from all Primary Care Trusts via a Freedom of Information request with regards to their SCS commissioning policy to determine whether a policy around the implementation of NICE guidance was in place or whether Individual Funding Requests (IFR) were being used.
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Results
The HES data analysis for year 2008-2012 showed a small increase in procedure codes 48.3 and 48.4 (Table 1a ) and large increase in procedure code 48.7. Figure 2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table 1a ). This was also evident with the East of England (29.8 procedures per million). Conversely, the lowest rates of SCS referrals were reported in regions with no PCT or SCG policy in place, such as the West Midlands and London (7.9 and 9.4 procedures per million, respectively).
.
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year of data is available therefore we are unable to comment on trends. Data for France was available for the last three years (Table 1b ) and shows no significant increase in SCS implants. The main indications for SCS are similar across the four countries i.e. failed back surgery syndrome or radicular pain, phantom pain, peripheral nerve injury, traumatic brachial plexus injury, spinal lesion, diabetic polyneuropathy and post herpetic neuralgia (7) . Focusing on the most common indication for SCS of failed back surgery syndrome, it is estimated that 10-40% of patients undergoing spinal surgery will develop neuropathic pain (15) . According to HES database, the number of spinal surgery procedures in England 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (17) . Assuming that one third of these procedures is being carried out for pain, the annual estimate will be 78,533 procedures of which 10% to 40 % (7,853 to 31,414) would be expected to be eligible for SCS treatment (16) . Based on this data, less than 2% of the eligible population of neuropathic patients in England are currently receiving SCS treatment. It is most plausible that Aa lack of awareness of SCS as a clinical and cost-effective treatment option amongst referring physicians may be is hindering the uptake of this NICE-approved technology. More constructive engagement with the wider population of patients and referring physicians by the neuromodulation community is warranted to ensure appropriate and early referral for SCS therapy.
Conclusion
Our study shows that NICE TA 159 has had minimal negligible impact on the uptake of SCS for new patients, and rates of SCS implantation were highly variable across Strategic
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